Cited by 389Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib

Open access

ADAPT Research Group*·2008·Archives of Neurology

DOI 10.1001/archneur.2008.65.7.nct70006PMC PMC2925195

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs. OBJECTIVE: To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults. DESIGN: Randomized, double-masked chemoprevention trial. SETTING: Six US memory clinics. PARTICIPANTS: Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment. INTERVENTIONS: Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively. MAIN OUTCOME MEASURES: Seven tests of cognitive function and a global summary score measured annually. RESULTS: Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]). Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences. Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses. CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archneur.2008.65.7.nct70006

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 402
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A. G., Ugoni, A., Vajda, F. J. E., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 385
Rofecoxib
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 384
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Self-citation
Reduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 317

Show all 20 references

Research works printed but not linked: 2

Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
Sainati S, Ingram D, Talwalker S, Geis G. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzhei- mer's disease. Presented at: The Sixth International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy; April 5-8, 2000; Stockholm, Sweden.

Sorted by citations

Items 201–300 of 389

The Role of Neuroinflammation in Neurodegenerative Disorders
Suescun, J., Chandra, S., & Schiess, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00013-3 · Cited by 34
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?
Huang, L., Chang, Y.-H., & Yang, Y. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00715-6 · Cited by 32
G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases
Guerram, M., Zhang, L., & Jiang, Z. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.09.005 · Cited by 32
Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions
Roberts, J. S., & Tersegno, S. M. (2010) · Future Neurology · doi:10.2217/fnl.10.31 · Cited by 32
Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases
Wittenberg, N. J., Wootla, B., Jordan, L. R., Đenić, A., Warrington, A. E., Oh, S., & Rodriguez, M. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.896199 · Cited by 31
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum
Bieger, A., Rocha, A., Bellaver, B., Machado, L. S., Ros, L. U. D., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S. G., et al. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.54 · Cited by 29
Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia
Ancelin, M., Carrière, I., Helmer, C., Rouaud, O., Pasquier, F., Berr, C., Chaudieu, I., & Ritchie, K. A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.038 · Cited by 31
A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer’s disease
Yeo, I. J., Lee, M. J., Baek, A., Miller, Z. C., Bhattarai, D., Baek, Y. M., Jeong, H. J., Kim, Y. K., Kim, D., Hong, J. T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54846-z · Cited by 29
Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer’s disease model
Liu, Y., Chen, W.-T., Lin, Y.-Y., Lu, P.-H., Hsieh, S.-L. E., & Cheng, I. H.-J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0173-0 · Cited by 29
Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?
Rommy von Bernhardi, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1248 · Cited by 28
Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimers Disease
Nagae, T., & Araki, K. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000441 · Cited by 28
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer’s Disease
Johansson, J. U., Woodling, N. S., Shi, J., & Andreasson, K. I. (2015) · Current Immunology Reviews · doi:10.2174/1573395511666150707181414 · Cited by 28
Investigational medications for treatment of patients with Alzheimer disease.
Potter, P. E. (2010) · PubMed · Cited by 27
Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs
Medrano-Jiménez, E., Meza‐Sosa, K. F., Aragon, J. A. U., Secundino, I., Pedraza-Alva, G., & Pérez-Martínez, L. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr1021-531r · Cited by 28
The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice
Ahmed, M. M., Wang, A. C., Elos, M. T., Chial, H. J., Sillau, S., Solano, D. A., Coughlan, C. M., Aghili, L., Anton, P. E., Markham, N. E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105694 · Cited by 31
The Current Landscape of Prevention Trials in Dementia
Lee, J., Howard, R. S., & Schneider, L. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01236-5 · Cited by 30
Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases
Catani, M. V., Gasperi, V., Bisogno, T., & Maccarrone, M. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6958 · Cited by 28
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities
Myasoedova, E., Sattui, S. E., Lee, J., O'Brien, J. T., & Makris, U. E. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00190-5 · Cited by 29
Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients
Boyd, H., & Booth‐Jones, M. (2012) · Brain Disorders & Therapy · doi:10.4172/bdt.1000101 · Cited by 25
The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials
Yaffe, K. S., Tocco, M., Petersen, R. C., Sigler, C., Burns, L. C., Cornelius, C., Khachaturian, A. S., Irizarry, M. C., & Carrillo, M. C. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.12.005 · Cited by 25
Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration
Wang, H., Ye, M., Yu, L., Wang, J., Guo, Y., Lei, W., & Yang, J. (2015) · Behavioral and Brain Functions · doi:10.1186/s12993-015-0054-z · Cited by 26
Disease Modifying Drugs Targeting β-Amyloid
Ozudogru, S. N., & Lippa, C. F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512452034 · Cited by 26
The promise of anti-inflammatory therapies for CNS injuries and diseases
Rivest, S. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.64 · Cited by 26
Role of Cyclooxygenase-2 and 5-Lipoxygenase Polymorphisms in Alzheimer's Disease in a Population from Northern Italy: Implication for Pharmacogenomics
Listı̀, F., Caruso, C., Lio, D., Colonna‐Romano, G., Chiappelli, M., Licastro, F., & Candore, G. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1260 · Cited by 25
Presence of severe neuroinflammation does not intensify neurofibrillary degeneration in human brain
Streit, W. J., Xue, Q., Braak, H., & Tredici, K. D. (2013) · Glia · doi:10.1002/glia.22589 · Cited by 24
Potential immunotherapy for Alzheimer disease and age-related dementia
Schwartz, M., Arad, M., & Ben-Yehuda, H. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/mschwartz · Cited by 25
Celecoxib Exerts Neuroprotective Effects in β-Amyloid-Treated SH-SY5Y Cells Through the Regulation of Heme Oxygenase-1: Novel Insights for an Old Drug
Mhillaj, E., Papi, M., Paciello, F., Silvestrini, A., Rolesi, R., Palmieri, V., Perini, G., Fetoni, A. R., Trabace, L., & Mancuso, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.561179 · Cited by 25
Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Prasad, K. N., & Bondy, S. C. (2014) · Current Aging Science · doi:10.2174/1874609807666140804115633 · Cited by 24
Implications of Gliotransmission for the Pharmacotherapy of CNS Disorders
Rossi, D., Martorana, F., & Brambilla, L. (2011) · CNS Drugs · doi:10.2165/11593090-000000000-00000 · Cited by 24
Patterns of anti‐inflammatory drug use and risk of dementia: a matched case–control study
Dregan, A., Chowienczyk, P., & Armstrong, D. (2015) · European Journal of Neurology · doi:10.1111/ene.12774 · Cited by 23
Cognitive Decline in Chronic Migraine with Nonsteroid Anti-inflammation Drug Overuse: A Cross-Sectional Study
Cai, X., Xu, X., Zhang, A., Lin, J., Wang, X., He, W., & Fang, Y. (2019) · Pain Research and Management · doi:10.1155/2019/7307198 · Cited by 23
Neuroinflammation and Alzheimer's disease: Unravelling the molecular mechanisms
Kakkar, A., Singh, H., Singh, B. K., Kumar, A., Mishra, A. K., & Chopra, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374353 · Cited by 26
Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort
Abdullah, L. I., Luis, C. A., Paris, D., Mouzon, B., Ait‐Ghezala, G., Keegan, A. P., Wang, D., Crawford, F., & MULLAN, M. J. (2009) · Molecular Medicine · doi:10.2119/molmed.2009.00083 · Cited by 22
Oligomeric Forms of Human Amyloid-Beta(1–42) Inhibit Antigen Presentation
Gericke, C., Mallone, A., Engelhardt, B., Nitsch, R. M., & Ferretti, M. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01029 · Cited by 20
Antiplatelets and Vascular Dementia: A Systematic Review
Alexander, P., Visagan, S., Jawhar, S., Kare, A. R., Issa, N., Issa, R., Jawhar, A., Thomas, S., & Gorantla, V. R. (2022) · Journal of Aging Research · doi:10.1155/2022/9780067 · Cited by 21
Epidemiology of Cognitive Aging and Alzheimer’s Disease: Contributions of the Cache County Utah Study of Memory, Health and Aging
Hayden, K. M., & Welsh-Bohmer, K. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_152 · Cited by 31
Celecoxib delays cognitive decline in an animal model of neurodegeneration
Borre, Y. E., Lemstra, S., Westphal, K. G. C., Morgan, M. E., Olivier, B., & Oosting, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.007 · Cited by 21
Do Microglia default on network maintenance in Alzheimer's disease?
Southam, K. A., Vincent, A. J., & Small, D. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151075 · Cited by 20
Drug repurposing for neurodegenerative diseases using Zebrafish behavioral profiles
Hernández, T. D. R., Gore, S. V., Kreiling, J. A., & Créton, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116096 · Cited by 18
A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17
Administration of Amyloid Precursor Protein Gene Deleted Mouse ESC-Derived Thymic Epithelial Progenitors Attenuates Alzheimer's Pathology
Zhao, J. X., Su, M., Lin, Y., Liu, H., He, Z., & Lai, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01781 · Cited by 19
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease
Vlieger, L. D., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103340 · Cited by 16
Arabidopsis thaliana extracts optimized for polyphenols production as potential therapeutics for the APOE-modulated neuroinflammation characteristic of Alzheimer’s disease in vitro
Ghura, S., Tai, L. M., Zhao, M., Collins, N., Che, C., Warpeha, K. M., & LaDu, M. J. (2016) · Scientific Reports · doi:10.1038/srep29364 · Cited by 17
Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin.
Pomponi, M. F. L., Gambassi, G., Pomponi, M., & Masullo, C. (2010) · Europe PMC (PubMed Central) · Cited by 15
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 16
Indomethacin Increases Neurogenesis across Age Groups and Improves Delayed Probe Trial Difference Scores in Middle-Aged Rats
McGuiness, J., Scheinert, R. B., Asokan, A., Stadler, V.-C., Lee, C. S., Rani, A., Kumar, A., Foster, T. C., & Ormerod, B. K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00280 · Cited by 15
Micheliolide attenuates neuroinflammation to improve cognitive impairment of Alzheimer's disease by inhibiting NF-κB and PI3K/Akt signaling pathways
Yang, G., Hu, Y., Qin, X., Sun, J., Miao, Z., Wang, L., Ke, Z., & Zheng, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17848 · Cited by 16
Anti-inflammatory drugs fall short in Alzheimer's disease
(2008) · Nature Medicine · doi:10.1038/nm0908-916 · Cited by 15
An update on the diagnosis and management of dementing conditions.
Maalouf, M., Ringman, J. M., & Shi, J. (2011) · PubMed · Cited by 15
Naproxen as a potential candidate for promoting rivastigmine anti-Alzheimer activity against aluminum chloride-prompted Alzheimer's-like disease in rats; neurogenesis and apoptosis modulation as a possible underlying mechanism
Abdel‐Aal, R. A., Hussein, O. A., Elsaady, R. G., & Abdelzaher, L. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174695 · Cited by 17
Neuroinflammation: A Driving Force in the Onset and Progression of Alzheimer’s Disease
Long, C., Fritts, A., Broadway, J., Brawman‐Mintzer, O., & Mintzer, J. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020331 · Cited by 20
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 14
Epidemiological findings of vascular risk factors in Alzheimer’s disease: implications for therapeutic and preventive intervention
Qiu, C. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.146 · Cited by 14
Neuroinflammation and Oxidative Stress in Alzheimer’s Disease; Can Nutraceuticals and Functional Foods Come to the Rescue?
Onaolapo, O. J., Olofinnade, A. T., Ojo, F. O., & Onaolapo, A. Y. (2021) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523021666220815151559 · Cited by 12
Sex‐ and region‐dependent neuroinflammation in Alzheimer's disease
Acosta‐Martínez, M., Carter, V., Nessim, A., Panchal, R., John, D., Dhawan, J., Beach, T. G., Serrano, G. E., Sundermann, E. E., & Biegon, A. R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14603 · Cited by 15
Is dementia preventable?
Korczyn, A. D. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/adkorczyn · Cited by 13
Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice
Vidal-Palencia, L., Ramon‐Duaso, C., González-Parra, J. A., & Busquets-García, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.864591 · Cited by 16
Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro
Zakrocka, I. N., Targowska‐Duda, K. M., Wnorowski, A., Kocki, T., Jóźwiak, K., & Turski, W. A. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9952-9 · Cited by 13
Drug Treatments in Development for Alzheimer's Disease
Woodward, M. C. (2012) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2012.tb00133.x · Cited by 12
Screening by Telephone in the Alzheimer's Disease Anti-inflammatory Prevention Trial
Reckess, G. Z., Brandt, J., Luis, C. A., Zandi, P. P., Martin, B. K., & Breitner, J. C. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130113 · Cited by 11
Beraprost sodium protects against chronic brain injury in aluminum-overload rats
Pan, Y., Yu, L., Lei, W., Guo, Y., Wang, J., Yu, H., Tang, Y. C., & Yang, J. (2015) · Behavioral and Brain Functions · doi:10.1186/s12993-014-0051-7 · Cited by 11
Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19
Potter, H., Boyd, T. D., Clarke, P., Pelak, V. S., & Tyler, K. L. (2020) · F1000Research · doi:10.12688/f1000research.23729.1 · Cited by 11
Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?
Bregman, N. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.52 · Cited by 11
Current Conceptual View of Alzheimer’s Disease
Herrup, K. (2012) · Advances in biological psychiatry · doi:10.1159/000335378 · Cited by 10
PGE2-EP3 signaling pathway contributes to protective effects of misoprostol on cerebral injury in APP/PS1 mice
Tian, X., Ji, C., Luo, Y., Yang, Y., Kuang, S., Mai, S., Ma, J., & Yang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8284 · Cited by 10
Type I Interferon Signaling Drives Microglial Dysfunction and Senescence in Human iPSC Models of Down Syndrome and Alzheimer's DiseasePreprint
Jin, M., Xu, R., Alam, M. M., Ma, Z., Zhu, S., Wang, L., Martini, A. C., Bernabucci, M., Xie, P., Kwan, K. Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985173 · Cited by 10
Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: Conceptual framework and example
Leoutsakos, J., Bartlett, A. L., Forrester, S., & Lyketsos, C. G. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1776 · Cited by 8
A qualitative analysis of an A β -monomer model with inflammation processes for Alzheimer’s disease
Ciuperca, I. S., Pujo-Menjouet, L., Tine, L. M., Torres, N., & Volpert, V. A. (2024) · Royal Society Open Science · doi:10.1098/rsos.231536 · Cited by 9
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders
Lasheen, N. N., Allam, S., Elgarawany, A., Aswa, D. W., Mansour, R., & Farouk, Z. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00933-4 · Cited by 12
Cell ageing: a flourishing field for neurodegenerative diseases
Brites, D. M. T. O. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.3.225 · Cited by 10
State of the Art of Anti-Inflammatory Drugs
Souza, T. R., Marques, G. S., Vieira, A. C. Q. D. M., & Freitas, J. C. R. (2012) · InTech eBooks · doi:10.5772/33817 · Cited by 9
Age of onset in genetic prion disease and the design of preventive clinical trialsPreprint
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haı̈k, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/401406 · Cited by 9
Association Between Inflammatory Markers and Cognitive Function in Adults With Bipolar Disorder: A Systematic Review
Coelho, D. R. A., Nicoloro‐SantaBarbara, J. M., Majd, M., Vieira, W. F., Laney, M. D., Lydston, M., Martins‐Filho, O. A., Bahia‐Oliveira, L. M. G., Salvi, J. D., Cassano, P., et al. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13824 · Cited by 8
Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Batool, S., Nawaz, M. S., Greig, N. H., Rehan, M., & Kamal, M. A. (2013) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523011312020004 · Cited by 8
Alzheimer's Prevention Initiative
Strobel, G. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101429 · Cited by 8
Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders
do Vale, F. D. A. C., Neto, Y. C., Bertolucci, P. H. F., Machado, J. C. B., da Silva, D. J., Allam, N., & Balthazar, M. L. F. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030005 · Cited by 8
Preventing Alzheimer’s Disease
Jones, R. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00003-1 · Cited by 8
Memory Complaints and Dementia
Kelley, R. E., & Minagar, A. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.09.008 · Cited by 9
Role of APOE and Age at Enrollment in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT)
Drye, L. T., & Zandi, P. P. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000341783 · Cited by 7
Neuroprotection in Alzheimer’s Disease
Jain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_8 · Cited by 7
Reelin Signaling, Hippocampal Neurogenesis, and Efficacy of Aspirin Intake & Stem Cell Transplantation in Aging and Alzheimer's disease.
Shetty, A. K. (2010) · PubMed Central · Cited by 7
Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
Shang, Y., Torrandell‐Haro, G., Vitali, F., Brinton, R. D., & (ADNI), T. A. D. N. I. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70074 · Cited by 7
Dental X-ray exposure and Alzheimer’s disease: A hypothetical etiological association
Rodgers, C. C. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.016 · Cited by 6
Synthesis and Preclinical Evaluation of 18F-Labeled Ketoprofen Methyl Esters for Cyclooxygenase-1 Imaging in Neuroinflammation.
Shukuri, M., Mawatari, A., Takatani, S., Tahara, T., Inoue, M., Arakaki, W., Ohno, M., Doi, H., & Onoe, H. (2022) · PubMed Central · doi:10.2967/jnumed.121.263713 · Cited by 6
Tratamento da doença de Alzheimer
de Assis, F., do Vale, C., Neto, Y. C., Bertolucci, P. H. F., Machado, J. C., da Silva, D. J., Allam, N., & Balthazar, M. L. F. (2011) · Dementia & Neuropsychologia · Cited by 6
Diabetes and cognitive dysfunction
Kim, B., Sims‐Robinson, C., Sakowski, S. A., & Feldman, E. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00027-7 · Cited by 8
NSAID exposure and risk of Alzheimer disease
Bennett, D. A., & Whitmer, R. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a81664 · Cited by 6
GM-CSF Promotes Immune Response and Survival in a Mouse Model of COVID-19Preprint
Kendall, L. V., Boyd, T. D., Sillau, S., Bosco‐Lauth, A. M., Markham, N. E., Fong, D. L., Clarke, P., Tyler, K. L., & Potter, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1213395/v1 · Cited by 6
The 2024 clinical practice guidelines on the pharmacological management of Behavioural and Psychological Symptoms of Dementia (BPSD) in the Arab world
Bokhari, S. A., Qassem, T., Al-Ayyat, D., Javaid, S. F., Sinawi, H. A., & Nasr, W. (2025) · Middle East Current Psychiatry · doi:10.1186/s43045-024-00495-6 · Cited by 6
The Role of Inflammation in Alzheimer’s Disease
Müller, N., Krause, D., Schwarz, M., Weidinger, E., & Reinisch, V. M. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_15 · Cited by 5
Neuroprotection in Alzheimer Disease
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_8 · Cited by 5
Pro-inflammatory Cytokine GM-CSF Improves Learning/Memory and Brain Pathology in Dp16 Down Syndrome Mice and Improves Learning/Memory in Wild-Type MicePreprint
Ahmed, M. M., Wang, A. C.-J., Elos, M. T., Chial, H. J., Sillau, S. H., Solano, D., Coughlan, C. M., Aghili, L., Anton, P., Markham, N., et al. (2021) · bioRxiv · doi:10.1101/2021.07.04.451073 · Cited by 2
Repurposed Drugs: Current Trends in Drug Discovery
Srikanth, G., Beda, D. P., & Kumar, N. P. (2024) · Pharmaceutical science. · doi:10.5772/intechopen.1006501 · Cited by 4
Emerging anti-inflammatory nanosystems targeted to the brain
Mahanta, A. K., Gothwal, A., Chaulagain, B., Muolokwu, C. E., Tagoe, B., Lamsal, B., Belin, M. A. F., & Singh, J. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2552103 · Cited by 4
Baicalin–Myricetin-Coated Selenium Nanoparticles Mitigate Pathology in an Aβ1-42 Mice Model of Alzheimer’s Disease
Gutiérrez, R. M. P., Gómez, J. T., Flores, J. M. M., Téllez, M. D. L. L. C., & Muñiz-Ramírez, A. (2025) · Pharmaceuticals · doi:10.3390/ph18091391 · Cited by 5
The Role of T Cells in Alzheimer's Disease Pathogenesis
Zhao, J., Wang, X., He, Y., Xu, P., Lai, L., Chung, Y., & Pan, X. (2023) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023050145 · Cited by 4
An optimal control problem for anti-inflammatory treatments of Alzheimer’s disease
Torres, N., Molina, E., & Pujo-Menjouet, L. (2025) · Journal of Mathematical Biology · doi:10.1007/s00285-025-02227-8 · Cited by 5
Are Inflammatory Profiles the Key to Personalized Alzheimer's treatment?
Brothers, H. M., & Wilcock, D. M. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.40 · Cited by 3
Cognitive Impairment in Parasitic Protozoan Infection
Chakroborty, N. K., Baksi, S., & Bhattacharya, A. (2023) · Springer eBooks · doi:10.1007/978-981-19-8225-5_4 · Cited by 3

Authors: ADAPT Research Group*
Affiliations: Johns Hopkins University (US)
Corresponding author: ADAPT Research Group*
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2008-07-01
Volume: 65
Issue: 7
Pages: 896
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneur.2008.65.7.nct70006
PMC: PMC2925195
OpenAlex: W1607135210
Cited by: 387
References: 20
Citations by year: 2026: 10 · 2025: 14 · 2024: 9 · 2023: 8 · 2022: 19 · 2021: 15 · 2020: 18 · 2019: 15 · 2018: 9 · 2017: 18 · 2016: 24 · 2015: 25 · 2014: 29 · 2013: 18 · 2012: 34
FWCI: 28.27
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Eisai
National Institute on Aging (U01AG015477, U01-AG15477)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: Alzheimer's disease, cognitive function, naproxen, celecoxib, nonsteroidal anti-inflammatory drugs, chemoprevention, dementia prevention, older adults, cognitive decline, ADAPT trial
MeSH terms: Celecoxib, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Cognition, Cognition Disorders, Double-Blind Method, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Naproxen, Pyrazoles, Sulfonamides, Time Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks